Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

02-102025

Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline ...
01-162025

Bio-Thera and World Medicine Signs an Exclusive License and Commercialisation Agreement for BAT2206, a Proposed Stelara® Biosimilar

Bio-TheraSolutions, a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosim...
01-142025

Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders

Guangzhou, China – Bio-Thera Solutions, Ltd. today announced thepublication of the Phase Iclinical study results for BAT...

上一页 ···7 8 9 10 11 ··· 下一页